An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing <i>Enterobacterales</i> and preventing resistance developmen
This study suggests that adjusting ceftazidime/avibactam dosing regimen based solely on eCLcr might be suboptimal for critically ill patients. Higher daily doses delivered by CI and adjusted based on TDM have the potential to improve aggressive joint PK/PD target attainment and potentially clinical/microbiological outcomes. Further investigations are warranted to confirm these findings and establish optimal TDM-guided dosing strategies for ceftazidime/avibactam in clinical practice.
Authors
- Matteo Rinaldi (ORCID: https://orcid.org/0000-0002-3568-5973)
- Simone Ambretti (ORCID: https://orcid.org/0000-0002-8358-339X)
- Milo Gatti (ORCID: https://orcid.org/0000-0003-3018-3779)
- Pierluigi Viale (ORCID: https://orcid.org/0000-0003-1264-0008)
- Pier Giorgio Cojutti (ORCID: https://orcid.org/0000-0001-7135-4410)
- Federico Pea (ORCID: https://orcid.org/0000-0002-6966-7167)
- Manjunath P. Pai (ORCID: https://orcid.org/0000-0001-7119-5034)
Institutions
- University of Michigan (US)
- Michigan Medicine (US)
- Azienda USL di Bologna (IT)
- University of Bologna (IT)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2024-08-19
- DOI
- https://doi.org/10.1093/jac/dkae290
- Citations
- 11
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.87